Cinda’s first SIRPα antibody, will CD47/SIRPα be the next piece of the Red Sea?

introduction

introduction

On September 8, the clinical application of the first domestic SIRPα monoclonal antibody IBI397 submitted by Innovent was accepted by the CDE
.

It is reported that IBI397 is a project introduced by Cinda Biotech and Alector, Inc.
in 2020 (R&D code AL008), and it has not entered the clinical stage at home and abroad

(Source: CDE official website)

IBI397 is an antibody that non-competitively inhibits SIRP-α/CD47 signaling.

It does not directly block the signaling pathway, but reduces the SIRP-α/CD47 pathway by inducing SIRP-α endocytosis and degradation on macrophages.
Signal to achieve the effect of lifting immunosuppression

CD47 -SIRPα pathway

CD47 -SIRPα pathway CD47 -SIRPα pathway CD47 -SIRPα pathway -SIRPα pathway

SIRPα is the Signal Regulatory Protein Alpha, which is mainly expressed on the surface of myeloid hematopoietic cells such as macrophages, monocytes, dendritic cells and granulocytes
.

CD47 (Leukocyte surface antigen) is one of the ligands of SIRPα .

SIRPα CD47 One of the ligands of SIRPα , CD47 binds to SIRP α to prevent macrophages from phagocytosis of normal cells.

(Targeting the mechanism of CD47-SIRPα pathway in tumors Source: [3])

Cinda Bio

Cinda Bio

Founded in 2011, Cinda Bio is committed to the development, production and sales of innovative drugs for the treatment of major diseases such as tumors
.

Cinda has deployed multiple high-potential targets in the oncology field, and has also made many major advances in non-tumor fields such as autoimmunity, metabolism and cardiovascular

5 commercial varieties money Dabo Shu ® up with ® Yau Su Lixin ® Dabo Hua ® Dabo Tan ® 6, paragraph 3.

(Tumor pipeline)

(Non-tumor pipeline)

Reference source:

Reference source: Reference source:

[1] CDE official website

[1] CDE official website

[2] Cinda Biological Semi-annual Report

[2] Cinda Biological Semi-annual Report

[3] Mark P.

[3] Mark P.

[4] Murata Y, Saito Y, Kotani T, Matozaki T.
Blockade of CD47 or SIRPα: a new cancer immunotherapy.
Expert Opin Ther Targets.
2020.